Localized administration of sodium nitroprusside: Enhances its protection against platelet aggregation in stenosed and injured coronary arteries

Texas Heart Institute Journal

Volumn 23, Issue 1, 1996, Pages 1-8

  Willerson, James T ^b   Igo, Stephen R ^a   Yao, Sheng Kun ^c   Ober, Judy C ^c   Macris, Michael P ^c   Ferguson, James J ^c  

^a Cormedics Corp ^*  (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

Animals; Coronary circulation drug effects; Cyclic GMP, dogs; Endothelium, vascular; Hemodynamics drug effects; Nitric oxide; Nitroprusside, intrapericardial, platelet aggregation drug effects

Indexed keywords

N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYHEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DOG; ENDOTHELIUM; INTRACARDIAC DRUG ADMINISTRATION; NONHUMAN; THROMBOCYTE AGGREGATION;

ADMINISTRATION, TOPICAL; ANIMALS; ARGININE; CORONARY CIRCULATION; CORONARY DISEASE; DOGS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; INJECTIONS, INTRAVENOUS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; PERICARDIUM; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; VASODILATOR AGENTS;

EID: 0029868891     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
3. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988,333: 664-6.
4. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990;87:5193-7.
5. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
6. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension Circulation 1993;87:1475-81.
7. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85: 1927-38.
8. Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989;80:1-9
9. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992,90:1168-72.
10. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991;88:1559-67.
11. Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992,86:1302-9
12. Golino P, Cappelli-Bigazzi M, Ambrosio G, Ragni M, Russolillo E, Condorelli M, et al Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res 1992;71:1447-56.
13. Kowaluk EA, Seth P, Fung HL. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle J Pharmacol Exp Ther 1992;262:916-22
14. Marks GS, McLaughlin BE, Brown LB, Beaton DE, Booth BP, Nakatsu K, et al Interaction of glyceryl trinitrate and sodium nitroprusside with bovine pulmonary vein homogenate and 10,000 x g supernatant: biotransformation and nitric oxide formation. Can J Physiol Pharmacol 1991;69:889-92.
15. Feelisch M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol 1991;17 (Suppl 3):S25-S33.
16. Bassenge E Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors. Eur Heart J 1991;12 (Suppl E):12-5.
17. Gryglewski RJ, Zembowicz A, Salvemini D, Taylor GW, Vane JR. Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin Br J Pharmacol 1992,106:838-45
18. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139 19-30.
19. Hawkins DJ, Meyrick BO, Murray JJ. Activation of guanylate cyclase and inhibition of platelet aggregation by endothelium-derived relaxing factor released from cultured cells. Biochim Biophys Acta 1988;969:289-96.
20. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-49.
21. Rovin JD, Stamler JS, Loscalzo J, Folts JD Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries J Cardiovasc Pharmacol 1993;22:626-31.
22. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976,54:365-70
23. Salvemini D, Radziszewski W, Korbut R, Vane J. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol 1990;101:991-5.
24. Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries Circulation 1984;69 1161-70
25. Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988;78:701-11.
26. Schumacher WA, Goldenberg HJ, Harris DN, Ogletree ML. Effect of thromboxane receptor antagonists on renal artery thiombosis in the cvnomolgus monkey. J Pharmacol Exp Ther 1987;243:460-6
27. 2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation 1993;88: 2888-93
28. Folts JD, Detmer DE, Nadler R. Possible platelet thrombi formation in dog and human femoral arteries. Tex Heart Inst J 1982;9.19-26.
29. Eichhorn EJ, Grayburn PA, Willard JE, Anderson HV, Bedotto JB, Carry M, et al. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patiente with severe angina. J Am Coll Cardiol 1991;17:43-52
30. Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, et al ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium injured canine coronary arteries. Circ Res 1992;70:39-48
31. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987,76-952-9
32. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986;73:572-8
33. Yao SK, Ober JC, Gonenne A, Clubb FJ Jr, Krishnaswami A, Ferguson JJ, et al. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res 1993;73:952-67.
34. Imamura T, Tamura K, Takenaga M, Nagatomo Y, Ishikawa T, Nakagawa S Intrapericardial OK-432 instillation for the management of malignant pericardial effusion. Cancer 1991; 68:259-63.
35. Cormican MC, Nyman CR. Intrapericardial bleomycin for the management of cardiac tamponade secondary to malignant pericardial effusion Br Heart J 1990;63.61-2.